Results 1 to 10 of about 8,618 (210)

sST2 and Heart Failure—Clinical Utility and Prognosis

Journal of Clinical Medicine, 2023
New parameters and markers are constantly being sought to help better assess patients with heart failure (HF). ST2 protein has gained interest as a potential biomarker in cardiovascular disease. It is known that the IL-33/ST2L system belongs to the cardioprotective pathway, which prevents the fibrosis, hypertrophy, and apoptosis of cardiomyocytes and ...
Magdalena Dudek, Marta Kałużna-Oleksy, Filip Sawczak   +2 more
exaly   +5 more sources

Sex and age differences in sST2 in cardiovascular disease

Frontiers in Cardiovascular Medicine, 2023
AimsThe goal of this study was to determine whether sex and age differences exist for soluble ST2 (sST2) for several cardiovascular diseases (CVDs).MethodsWe examined sST2 levels using an ELISA kit for myocarditis (n = 303), cardiomyopathy (n = 293 ...
Danielle J. Beetler, Danielle J. Beetler, Danielle J. Beetler, Katelyn A. Bruno, Katelyn A. Bruno, Damian N. Di Florio, Damian N. Di Florio, Damian N. Di Florio, Erika J. Douglass, Swikriti Shrestha, Swikriti Shrestha, Swikriti Shrestha, Carsten Tschöpe, Carsten Tschöpe, Carsten Tschöpe, Madeleine W. Cunningham, Jan Krejčí, Jan Krejčí, Julie Bienertová-Vašků, Julie Bienertová-Vašků, Sabine Pankuweit, Dennis M. McNamara, Dennis M. McNamara, Eun-Seok Jeon, Sophie van Linthout, Sophie van Linthout, Lori A. Blauwet, Leslie T. Cooper, DeLisa Fairweather, DeLisa Fairweather, DeLisa Fairweather   +30 more
doaj   +4 more sources

sST2 as a value-added biomarker in heart failure [PDF]

Clinica Chimica Acta, 2020
Soluble suppression of tumorigenicity-2 (sST2) is a biomarker widely investigated during the last few years. Its role has become clear in pathological conditions such as fibrosis and inflammation. From translational research to laboratory medicine, considerable efforts have been made to elucidate the features of sST2 biomarker and to consider its ...
Manuela Lotierzo, Anne-Marie Dupuy, Eran Kalmanoviche   +2 more
exaly   +4 more sources

Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: A systematic review and meta-analysis

IJC Heart and Vasculature, 2021
Objectives: Soluble suppression of tumorigenicity 2 (sST2) is a member of the interleukin-1 receptor family. It is raised in various cardiovascular diseases, but its value in predicting disease severity or mortality outcomes has been controversial ...
Kevin Ho, Keith Sai Kit Leung, George Bazoukis   +2 more
exaly   +4 more sources

Epigenetic regulation of SST2 expression in small intestinal neuroendocrine tumors

Frontiers in Endocrinology, 2023
BackgroundSomatostatin receptor type 2 (SST2) expression is critical for the diagnosis and treatment of neuroendocrine tumors and is associated with improved patient survival.
Maria J. Klomp, Maria J. Klomp, Julie Refardt, Julie Refardt, Peter M. van Koetsveld, Claudia Campana, Claudia Campana, Simone U. Dalm, Fadime Dogan, Marie-Louise F. van Velthuysen, Richard A. Feelders, Wouter W. de Herder, Johannes Hofland, Leo J. Hofland   +13 more
doaj   +2 more sources

Serum sST2 levels predict severe exacerbation of asthma [PDF]

Respiratory Research, 2018
Background Neutrophilic inflammation is associated with poorly controlled asthma. Serum levels of sST2, a soluble IL-33 receptor, increase in neutrophilic lung diseases. We hypothesized that high serum sST2 levels in stable asthmatics are a predictor for
Masato Watanabe, Keitaro Nakamoto, Toshiya Inui, Mitsuru Sada, Kojiro Honda, Masaki Tamura, Yukari Ogawa, Takuma Yokoyama, Takeshi Saraya, Daisuke Kurai, Haruyuki Ishii, Hajime Takizawa   +11 more
doaj   +3 more sources

Primary sources and immunological prerequisites for sST2 secretion in humans [PDF]

Cardiovascular Research, 2010
Serum levels of the soluble growth stimulation gene-2 (sST2) are elevated in heart and pulmonary diseases. However, the relationship of the sST2/interleukin (IL)-33 axis and its triggers as well as its organ distribution is still not known. This study was thus designed to investigate the cellular origin and regulation of sST2 and IL-33 in vitro and in ...
Michael Mildner, Michael Lichtenauer, Konrad Hoetzenecker   +2 more
exaly   +3 more sources

Plasma Soluble ST2 as a Prognostic Biomarker for Cardiovascular Events and Mortality in COVID-19 Patients [PDF]

Journal of Cardiovascular Development and Disease
Background: Coronavirus disease 2019 (COVID-19) is frequently complicated by cardiovascular involvement. Soluble growth stimulation-expressed gene 2 (sST2) is a promising cardiovascular biomarker, but its prognostic value in COVID-19 remains unclear ...
Yongcui Yan, Yan Zhuang, Huihui Li, Dao Wen Wang   +3 more
doaj   +2 more sources

The elevated levels of soluble growth stimulation expressed gene 2 are associated with coronary atherosclerotic plaque destabilization in unstable angina patients: a case control study [PDF]

BMC Cardiovascular Disorders
Background Plaque destabilization and rupture are the primary triggers of acute coronary syndrome (ACS). Soluble growth stimulation expressed gene 2 (sST2) has been implicated in cardiovascular disease.
Ning Li, Xinjian Li, Lin Ni, Xuewen Li
doaj   +2 more sources

Soluble ST2 levels for predicting the presence and severity of metabolic syndrome

Endocrine Connections, 2021
To explore the relationship between soluble ST2 (sST2) and metabolic syndrome (MetS) and determine whether sST2 levels can predict the presence and severity of MetS.
Xiao Zong, Qin Fan, Hang Zhang, Qian Yang, Hongyang Xie, Qiujing Chen, Ruiyan Zhang, Rong Tao   +7 more
doaj   +1 more source